

Revision date: 02-Jan-2007 Version: 2.3 Page 1 of 9

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

Material Name: Doxycycline calcium oral suspension syrup

Trade Name: Vibramycin(R)
Chemical Family: Mixture

Intended Use: Pharmaceutical product used as antibiotic agent

## 2. COMPOSITION/INFORMATION ON INGREDIENTS

### **Hazardous**

Ingredient	CAS Number	<b>EU EINECS List</b>	%
Doxycycline calcium	94088-85-4	302-088-9	1
Hydrogen chloride	7647-01-0	231-595-7	*
Magnesium aluminum silicate	1327-43-1	215-478-8	*
Calcium chloride USP	10035-04-8	Not listed	*
Glycerin, USP	56-81-5	200-289-5	*
Sodium hydroxide	1310-73-2	215-185-5	*
Sodium metabisulfite USP	7681-57-4	231-673-0	*

Ingredient	CAS Number	<b>EU EINECS List</b>	%
Sorbitol	6706-59-8	Not listed	*
Rasberry flavor	NOT ASSIGNED	Not listed	*
Butylparaben	94-26-8	202-318-7	*
Simethicone emulsion	67762-90-7	Not listed	*
Povidone	9003-39-8	Not listed	*
Propylparaben	94-13-3	202-307-7	*
Carmine no. 40 - FCC	NOT ASSIGNED	Not listed	*
Apple flavor, artificial	NOT ASSIGNED	Not listed	*
Propylene glycol	57-55-6	200-338-0	*
Water, purified	7732-18-5	231-791-2	*

Additional Information: \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

## 3. HAZARDS IDENTIFICATION

Appearance: Raspberry-apple flavored syrup

Signal Word: WARNING

Material Name: Doxycycline calcium oral suspension syrup

Revision date: 02-Jan-2007 Version: 2.3

Statement of Hazard: Infants of mothers exposed during pregnancy may develop discoloration of the teeth

May cause allergic reaction in sensitive individuals

May cause liver toxicity

**Additional Hazard Information:** 

Short Term: May cause allergic reactions in susceptible individuals. Accidental ingestion may cause effects

similar to those seen in clinical use.

Known Clinical Effects: May cause permanent discoloration of teeth if used during tooth development. May cause

effects similar to those generally seen in clinical use of tetracyclines including gastrointestinal

Page 2 of 9

irritation, nausea, vomiting, and diarrhea. Photosensitivity has been reported in some

individuals taking tetracyclines.

**EU Indication of danger:** Toxic to reproduction: Category 1

**EU Hazard Symbols:** 



**EU Risk Phrases:** 

R63 - Possible risk of harm to the unborn child.

**Note:** This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

## 4. FIRST AID MEASURES

**Eye Contact:** Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get

medical attention.

**Skin Contact:** Wash skin with soap and water. Remove contaminated clothing and shoes. This material may

not be completely removed by conventional laundering. Consult professional laundry service.

Do not home launder. If irritation occurs or persists, get medical attention.

Ingestion: Get medical attention immediately. Do not induce vomiting unless directed by medical

personnel. Never give anything by mouth to an unconscious person.

**Inhalation:** Remove to fresh air. If not breathing, give artificial respiration. Get medical attention

immediately.

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride

and other chlorine-containing compounds.

Fire Fighting Procedures: Wear approved positive pressure, self-contained breathing apparatus and full protective turn

out gear. Evacuate area and fight fire from a safe distance.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

## 6. ACCIDENTAL RELEASE MEASURES

Material Name: Doxycycline calcium oral suspension syrup

Revision date: 02-Jan-2007 Version: 2.3

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

**Measures for Environmental** 

**Protections:** 

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

Page 3 of 9

avoid environmental release.

**Additional Consideration for Large** 

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

General Handling: Use with adequate ventilation. Avoid breathing vapor or mist. Wash thoroughly after handling.

Storage Conditions: Keep container tightly closed when not in use. Store in a cool, dry place away from direct

sunlight.

Storage Temperature: <30°C

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Doxycycline calcium

Pfizer OEL TWA-8 Hr: 0.25 mg/m<sup>3</sup>

Hydrogen chloride

ACGIH Ceiling Threshold Limit: = 2 ppm Ceiling

Australia PEAK = 5 ppm Peak

= 7.5 mg/m<sup>3</sup> Peak

Glycerin, USP

**OSHA - Final PELS - TWAs:** = 15 mg/m<sup>3</sup> TWA total

= 5 mg/m<sup>3</sup> TWA = 10 mg/m<sup>3</sup> TWA

ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA Australia TWA = 10 mg/m³ TWA

Sodium hydroxide

OSHA - Final PELS - TWAs: 2 mg/m<sup>3</sup>

ACGIH Ceiling Threshold Limit: = 2 mg/m³ Ceiling Australia PEAK = 2 mg/m³ Peak

Sodium metabisulfite USP

ACGIH Threshold Limit Value (TWA) =  $5 \text{ mg/m}^3 \text{ TWA}$ Australia TWA =  $5 \text{ mg/m}^3 \text{ TWA}$ 

Propylene glycol

Australia TWA = 10 mg/m<sup>3</sup> TWA

= 150 ppm TWA = 474 mg/m<sup>3</sup> TWA

The exposure limit(s) listed for solid components are only relevant if dust or mist may be generated.

Analytical Method: Analytical method available for Doxycycline. Contact Pfizer Inc for further information.

**Engineering Controls:** Keep airborne contamination levels below the exposure limits listed above in this section.

General room ventilation is adequate unless the process generates dust, mist or fumes.

**Personal Protective Equipment:** 

Material Name: Doxycycline calcium oral suspension syrup

Revision date: 02-Jan-2007 Version: 2.3

Hands: Rubber gloves

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

Skin: Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and

laboratory areas.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

Page 4 of 9

## 9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:SyrupColor:RedOdor:Light rasberryMolecular Formula:Mixture

Molecular Weight: Mixture

## 10. STABILITY AND REACTIVITY

Stability: Stable

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: Strong oxidizers

Hazardous Decomposition Products: No data available See Section 5 - under Hazardous combustion products.

Polymerization: Will not occur

## 11. TOXICOLOGICAL INFORMATION

**General Information:** The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

## Hydrogen chloride

Rat Inhalation LC50 1H 3,124 ppm Mouse Inhalation LC50 1H 1,108 ppm

Mouse Oral LD50 900 mg/kg

### Sodium hydroxide

Mouse IP LD50 40 mg/kg

#### Propylene glycol

Mouse Oral LD50 22,000 mg/kg Rat Oral LD50 20,000 mg/kg Rabbit Dermal LD50 20,800 mg/kg

#### **Povidone**

Rat Oral LD50 100 g/kg

### Propylparaben

Mouse Oral LD 50 6332 mg/kg

Mouse Intraperitoneal LD 50 200 mg/kg

Glycerin, USP

Page 5 of 9

Material Name: Doxycycline calcium oral suspension syrup

Revision date: 02-Jan-2007 Version: 2.3

Mouse Oral LD50 4090 mg/kg Rat Oral LD50 12.6 g/kg

Rabbit Dermal LD50 > 10 g/kg Rat Inhalation LC50 1hr > 570 mg/m<sup>3</sup>

Rat Dermal LD 50 >21.9 g/kg

#### Calcium chloride USP

Rat Oral LD50 1000 mg/kg Mouse Oral LD50 1940 mg/kg

#### Doxycycline calcium

Mouse Oral LD50 1900 mg/kg (hydrochloride) Rat Oral LD50 > 2000 mg/kg (hydrochloride)

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Inhalation Acute Toxicity

Tetracyclines are known to cause local irritation upon intramuscular and intravenous

administration. The potential for irritation should be considered.

**Ingestion Acute Toxicity** See Acute toxicity table.

### Irritation / Sensitization: (Study Type, Species, Severity)

### Sodium hydroxide

Eye Irritation Rabbit Severe Skin Irritation Rabbit Severe

#### Propylene glycol

Skin Irritation Rabbit Mild Eye Irritation Rabbit Mild

### Glycerin, USP

Eye Irritation Rabbit Mild

Eye Irritation / Sensitization Tetracyclines are known to cause local irritation upon intramuscular and intravenous

administration. The potential for irritation should be considered.

**Skin Irritation / Sensitization**Tetracyclines are known to cause local irritation upon intramuscular and intravenous

administration. The potential for irritation should be considered. Photosensitivity manifested

by an exaggerated sunburn reaction has been observed in some individuals taking

tetracyclines.

### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Propylparaben

**Chronic Toxicity** 

3 Week(s) Rat Oral 27.1 g/kg LOAEL Endocrine system

4 Week(s) Rat Oral 347.2 mg/kg LOAEL Male reproductive system

**Subchronic Effects**Rats administered oral doses up to 500 mg/kg/day for 30 days showed no toxic effects.

Chronic toxicity was evaluated in rats at oral doses up to 500 mg/kg/day for 18 months. Findings revealed no adverse effects on growth, food consumption, or survival. Yellow ultraviolet fluorescence of bone, teeth and/or kidneys was seen in rats at all levels. Chronic studies in dogs at oral doses up to 100 mg/kg/day for one year showed some functional and histopathological changes in the liver. However, effects were reversible after cessation of

exposure to the material.

Chronic Effects/Carcinogenicity No long-term toxicity studies have been conducted to evaluate the chronic toxicity or

carcinogenic potential of this material.

Reproductive Effects Fertility studies of doxycycline in female rats at oral doses up to 250 mg/kg/day showed no

adverse effects.

**Teratogenicity**No teratogenic effects were observed in monkeys at oral doses of doxycycline HCl ranging

from 1 to 50 mg/kg/day. Tetracyclines as a class are capable of crossing the placenta and

causing permanent discoloration of the teeth. Liver Reproductive system

Material Name: Doxycycline calcium oral suspension syrup

Revision date: 02-Jan-2007 Version: 2.3

Mutagenicity No data available however, positive results in in vitro mammalian cell assays have been

reported for related antibiotics.

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Hydrogen chloride

IARC: Group 3

**Povidone** 

IARC: Group 3

Sodium metabisulfite USP

IARC: Group 3

At increase risk from exposure: Individuals who have shown hypersensitivity to this material or other materials in its chemical

class and individuals with liver and/or kidney dysfunction or impairment may be more

Page 6 of 9

susceptible to toxicity in cases of overexposure.

Additional Information: FDA PREGNANCY CATEGORY D. Positive evidence of human fetal risk from marketing

experience or human studies.

## 12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to

the environment should be avoided.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Glycerin, USP

Oncorhynchus mykiss (Rainbow Trout) LD50 96 Hours 50 mg/L

Daphnia Magna (Water Flea) EC50 24 Hours >500 mg/L

Aquatic Toxicity Comments: A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum

dose tested.

## 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations.

## 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## 15. REGULATORY INFORMATION

EU Symbol:

**EU Indication of danger:** Toxic to reproduction: Category 1

**EU Risk Phrases:** 

R63 - Possible risk of harm to the unborn child.

Material Name: Doxycycline calcium oral suspension syrup

Revision date: 02-Jan-2007 Version: 2.3

#### **EU Safety Phrases:**

S53 - Avoid exposure - obtain special instructions before use.

#### **OSHA Label:**

**WARNING** 

Infants of mothers exposed during pregnancy may develop discoloration of the teeth May cause allergic reaction in sensitive individuals May cause liver toxicity

#### Canada - WHMIS: Classifications

#### WHMIS hazard class:

Class D, Division 2, Subdivision A



Doxycycline calcium

California Proposition 65 developmental toxicity, initial date 1/1/92 (internal use)

EU EINECS List 302-088-9

Butylparaben

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
202-318-7

Hydrogen chloride

**CERCLA/SARA 313 Emission reporting** = 1.0 % de minimis concentration acid aerosols including mists,

vapors, gas, fog, and other airborne forms of any particle size

Page 7 of 9

**CERCLA/SARA Hazardous Substances** = 2270 kg final RQ and their Reportable Quantities: = 5000 lb final RQ

CERCLA/SARA - Section 302 Extremely Hazardous = 500 lb TPQ gas only

TPQs

CERCLA/SARA - Section 302 Extremely Hazardous = 5000 lb EPCRA RQ gas only

Substances EPCRA RQs Inventory - United States TSCA - Sect. 8(b)

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Standard for the Uniform Scheduling

Schedule 5

For Private and Reigens:

for Drugs and Poisons:Schedule 6EU EINECS List231-595-7

Simethicone emulsion

Inventory - United States TSCA - Sect. 8(b) XU
Australia (AICS): Present

Magnesium aluminum silicate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
215-478-8

Calcium chloride USP

Material Name: Doxycycline calcium oral suspension syrup

Page 8 of 9 Revision date: 02-Jan-2007 Version: 2.3

Australia (AICS): Present

**Povidone** 

XU Inventory - United States TSCA - Sect. 8(b) Australia (AICS): Present

Propylparaben

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS List** 202-307-7

Glycerin, USP

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS List** 200-289-5

Sodium hydroxide

**CERCLA/SARA Hazardous Substances** = 1000 lb final RQ and their Reportable Quantities: = 454 kg final RQ

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present Standard for the Uniform Scheduling Schedule 5 for Drugs and Poisons: Schedule 6 **EU EINECS List** 215-185-5

Sodium metabisulfite USP

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present Standard for the Uniform Scheduling Schedule 5

for Drugs and Poisons:

**EU EINECS List** 231-673-0

Propylene glycol

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS List** 200-338-0

Water, purified

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS List** 231-791-2

## **16. OTHER INFORMATION**

Reasons for Revision: Updated Section 3 - Hazard Identification. Updated Section 6 - Accidental Release Measures.

Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations. Updated Section 15 - Regulatory

Information.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

Material Name: Doxycycline calcium oral suspension syrup Revision date: 02-Jan-2007 Page 9 of 9 Version: 2.3